Oertel W H, Schwarz J, Tatsch K, Arnold G, Gasser T, Kirsch C M
Department of Neurology, Klinikum Grosshadern, Ludwig-Maximilians-University Munich, Germany.
Adv Neurol. 1993;60:519-24.
IBZM-SPECT is useful as a predictor for the responsiveness to oral L-DOPA therapy in de novo parkinsonian patients. A reduction of postsynaptic dopamine D2 receptors in de novo parkinsonian patients makes the diagnosis of Parkinson's disease rather unlikely. Normal IBZM binding does not prove the diagnosis of Parkinson's disease; however, together with a positive apomorphine test, it strongly supports the clinical diagnosis. At present the combination of IBZM-SPECT and apomorphine testing appears to be a useful procedure for selecting de novo patients for clinical trials with new anti-parkinsonian therapy.
碘苄胍单光子发射计算机断层扫描（IBZM-SPECT）可作为初发帕金森病患者对口服左旋多巴治疗反应性的预测指标。初发帕金森病患者突触后多巴胺D2受体减少，这使得帕金森病的诊断不太可能成立。IBZM结合正常并不能确诊帕金森病；然而，结合阿扑吗啡试验呈阳性，则强烈支持临床诊断。目前，IBZM-SPECT与阿扑吗啡试验相结合似乎是一种有用的方法，可为新的抗帕金森病治疗的临床试验筛选初发患者。
